Nicotinic receptor antagonists and pioglitazone as therapeutic agents for Covid-19
AssigneeUniversity of South Florida
InventorsPaul Ronald Sanberg, Christian Bernard Brechot, Shyam S. Mohapatra, Subhra Mohapatra
Life of this patent
Estimating the term…
Abstract
A method of treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), otherwise known as COVID-19, infection by administering nicotinic receptor antagonists and/or PPAR-γ agonists is presented. A combination of mecamylamine, or an isomer thereof, and pioglitazone synergistically reduces replication of SARS-CoV-2 in virus-infected cells and also synergistically reduces inflammatory cytokines such as IL-6, IL-β, and TNFα, which have been associated with SARS-CoV-2 infection.
Claims12
A method of treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a patient in need thereof comprising:
- administering to the patient in need thereof a therapeutically effective amount of a composition comprising
- a nicotinic receptor antagonist wherein the nicotinic receptor antagonist is mecamylamine or a stereoisomer thereof;
- a peroxisome proliferator activated receptor gamma (PPAR-γ) agonist wherein the PPAR-γ agonist is pioglitazone;
- and
- a pharmaceutically acceptable carrier;
- wherein the nicotinic receptor antagonist and the PPAR-γ agonist act synergistically to treat the SARS-CoV-2 in the patient by reducing cytokine storm caused by inflammatory cytokine overexpression.
A method of decreasing severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infection in a patient in need thereof comprising:
- administering to the patient in need thereof a therapeutically effective amount of a composition comprising
- a nicotinic receptor antagonist wherein the nicotinic receptor antagonist is mecamylamine or a stereoisomer thereof;
- a peroxisome proliferator activated receptor gamma (PPAR-γ) agonist wherein the PPAR-γ agonist is pioglitazone;
- and
- a pharmaceutically acceptable carrier;
- wherein the nicotinic receptor antagonist and the PPAR-γ agonist act synergistically to reduce cytokine storm caused by inflammatory cytokine overexpression and SARS-CoV-2 replication in virus-infected cells of the patient.
A method of decreasing inflammatory cytokine expression in a patient infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) comprising:
- administering to the patient in need thereof a therapeutically effective amount of a composition comprising
- a nicotinic receptor antagonist wherein the nicotinic receptor antagonist is mecamylamine or a stereoisomer thereof;
- a peroxisome proliferator activated receptor gamma (PPAR-γ) agonist wherein the PPAR-γ agonist is pioglitazone;
- and
- a pharmaceutically acceptable carrier;
- wherein the nicotinic receptor antagonist and the PPAR-γ agonist act synergistically to decrease the inflammatory cytokine expression in the patient.
Dependencies are inferred from the claim text.